

DAFTAR PUSTAKA

1. University of Rochester Medical Center. Top 10 Most Common Health Issues. New York: The University; 2013;4–7.
2. World Health Organization (2018). HIV/AIDS Data and Statistics 2018. Available from: http://www.who.int/hiv/data/2017_summary-global-hiv-epidemic.png – Diakses Oktober 2018.
3. Asfiah N. Pencegahan Penyebaran HIV/AIDS Melalui Penguatan Budaya. HUMANITY. 2011;6:116–20.
4. Joint United Nations Programme on HIV/AIDS (2018) . UNAIDS DATA 2018. Available from: http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf – Diakses Oktober 2018.
5. Yuni H. Analisis Faktor Faktor yang Berhubungan dengan Kepatuhan ARV di Poliklinik VCT RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2017;6
6. Diatmi K, Diah IG. Hubungan Antara Dukungan Sosial dengan Kualitas Hidup pada Orang Dengan HIV dan AIDS (ODHA) Di Yayasan Spirit Paramacitta. J Psikol Udayana. 2014;1(2):353–62.
7. University of Bristol. Survival of HIV- Positive Patients Starting Antiretroviral Therapy Between 1996 and 2013: Collaborative Analysis Of Cohort Studies. Bristol: The University; 2017;349–56.
8. Sumantri R. Kegagalan Terapi Infeksi HIV / AIDS dan Resistensi Antiretroviral. Glob Med Heal Commun. 2013;1(1):31–3.
9. Yuliandra Y, Nosa US, Raveinal R, Almasdy D. Terapi Antiretroviral pada Pasien HIV/AIDS di RSUP. Dr. M. Djamil Padang: Kajian Sosiodemografidan Evaluasi Obat. J Sains Farm Klin. 2017 Dec 15;4(1):1.
10. Clavel, Francois J, Allan M H. Medical Progress: HIV Drug Resistance. N Engl J Med. 2004;350(10):1023–35.
11. Muktiarti D, Munasir Z, Kurniati N. Terapi Antiretroviral Lini Kedua pada HIV Anak di RS. Cipto Mangunkusumo. Sari Pediatr. 2012;14(2).
12. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan

- Republik Indonesia Nomor 87 Tahun 2014. Kementrian; 2015.
13. Nurtakyidah. Studi Penggunaan Obat di Unit Perawatan Intensif Umum Rumah Sakit DR. Hasan Sadikin Bandung. *J Iqra*. 2013;7(2):41–52.
 14. WHO (2015). Report A. Essential Medicines and Health Products The Pursuit of Responsible Use of Medicines: Sharing and Learning from Country Experiences. Available from: http://www.who.int/medicines/areas/rational_use/en/ Diakses Oktober 2018.
 15. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA, editors. *Jawetz, Melnick and Aldelberg's Medical Microbiology*. New York: McGraw-Hill Companies;2013..
 16. Alwi I, Sudoyo AW. Buku Ajar Ilmu Penyakit Dalam. In: Djoerban Z, Djauzi S, editors. *Infeksi HIV dan AIDS*. Jakarta: Interna Publishing; 2014. p. 887 - 924
 17. Pagadala M. HIV-AIDS. *Allg Homöopathische Zeitung*. 2017;262(02):2–76.
 18. Nsuami MU, Witbooi PJ. A Model of HIV/AIDS Population Dynamics Including ARV Treatment And Pre-Exposure Prophylaxis. *Adv Differ Equations*. 2018;2018(1):1–12.
 19. Ministry of Health of the Republic Indonesia. *Kajian Epidemiologi HIV Indonesia 2016*. Jakarta: The Ministry; 2017.
 20. Dinas Kesehatan Kota Padang. *Profil Kesehatan Kota Padang*. Padang : Instansi; 2018.
 21. Dias MVS, Costa CS, DaSilva LLP. The Ambiguous Roles of Extracellular Vesicles in HIV Replication and Pathogenesis. *Frontiers in Microbiology*. 2018;9:1–13.
 22. Adojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K, et al. Predominance of A Rare Type Of HIV-1 In Estonia. *JAIDS, J Acquir Immune Defic Syndr*. 2005;39(5):598–605.
 23. Center for Disease Control and Prevention. *About HIV/AIDS*. Atlanta; The Institute; 2018.

24. WHO (2018). HIV/AIDS Key Facts 2018. Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> - Diakses Oktober 2018.
25. Kristensen S, Sinkala M, Vermund SH. Transmission of HIV/AIDS Africa. *Int J STD AIDS*. 2002;(1):217–30.
26. Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV reservoirs. *Rev Med Virol*. 2017;27(2):1–12.
27. Sleasman JW, Goodenow MM. HIV-1 Infection. *J Allergy Clin Immunol*. 2003;111:582–92.
28. UNAIDS (2018). JUNP on H. Fact Sheet July 2018 Global Hiv Statistics. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf – Diakses Oktober 2018.
29. Soliman M, Srikrishna G, Balagopal A. Mechanisms of HIV-1 Control. *Curr HIV/AIDS Rep*. 2017;14(3):101–9
30. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. *Nature*. 2001;410(6831):980–7.
31. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, et al. The Qualitative Nature Of The Primary Immune Response To HIV Infection Is A Prognosticator Of Disease Progression Independent of The Initial Level Of Plasma Viremia. *Proceedings of the National Academy of Sciences*. 1997;94:254–8
32. Center for Disease Control and Prevention. Stages of HIV Infection. Atlanta; The Institute; 2013.
33. Rastogi S, Agrahari S, Ganga S, Hospital R, Singh UP, Verma A. Clinical Stages of HIV. *Biolixir*. 2011;I:29–31.
34. Wood BR, Spach DH. Acute and Recent HIV Infection. *CME* 2017;10:1-11.
35. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa. Jakarta : Kementrian; 2011.

36. Ministry of Health and Family Welfare Government of India. Guidelines for Prevention and Management of Common Opportunistic Infections/Malignancies among HIV-infected Adult and Adolescent. New Delhi: Ministry; 2007.
37. Shen L, Farid H, Mcpeek MA. Mental Health Practitioner's Guide to HIV/AIDS. Loue S, Biostatistics D of E and, University CWR, Cleveland O, USA, editors. Evolution. New York: Springer; 2013;I:95–97
38. Page M, Taylor S. Diagnosis, Treatment, and Prevention of STIs and HIV Antiretroviral. Med (United Kingdom). 2018;46(5):287–92.
39. Yasin NM, Maranty H, Ningsih R. Response to Antiretroviral Therapy Undergone by HIV/AIDS Patients. Maj Farm Indones. 2011;22(3):212–22.
40. Karyadi TH. Keberhasilan Pengobatan Antiretroviral (ARV). J Penyakit Dalam Indones. 2017;4(1):2–4.
41. Nasronudin. HIV dan AIDS : Pendekatan Biologi Molekuler, Klinis, dan Sosial. Surabaya: Airlangga University Press; 2007. p. 9-10
42. Latif F, Maria IL, Syafar M. Drug Side Effects on Adherence to Antiretroviral Treatment among People Living with HIV/AIDS. J Kesehat Masy Nas. 2014;9(2):101–6.
43. Salwa A. Evaluasi Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Dengan Gagal Ginjal di Instalansi Rawat Inap RSUD Dr. Moewardi Tahun 2010. J Chem Inf Model. 2013;53:1–2.
44. Academy of Manage Care Pharmacy. Drug Utilization Review. Manag Care Pharm Pract. Washington: The Institute; 2008.
45. Kementerian Kesehatan Republik Indonesia. Modul Penggunaan Obat Rasional. Jakarta: Kementrian; 2011.
46. Supardi. Populasi Dan Sampel Penelitian. Unisia. 1990;17:100–108.
47. Dahlan MS. Langkah-Langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan. Vol. 34. Jakarta: Salemba Medika; 2012.
48. Zetola NM, Pilcher CD. Diagnosis and Management of Acute HIV Infection.

- Infect Dis Clin N Am. 2007;21:19–48.
49. Kurnia DA, Solekhah U. Hubungan Pengetahuan HIV/AIDS, Terapi Antiretroviral, dan Infeksi Oportunistik Terhadap Kepatuhan ODHA dalam Menjalani Terapi Antiretroviral. *J Heal*. 2018;5(2):84–7.
 50. Prabowo A, Yudasubrata NSY, Tripena A. Hubungan antara Kelompok Umur, Jenis Kelamin, dan Jenis Pekerjaan pada Penderita HIV/AIDS di Kabupaten Banyumas. *Pros Call f Pa* 2017;1779–87.
 51. Musthofa SB, Winarti F. The Influencing Factors of a Pre-Marital Sexual Behavior Among College Students in Pekalongan. *J Kesehat Repro* 2010;1(1):33-41
 52. Yogani I, Karyadi TH, Uyainah A, Koesnoe S. Faktor-faktor yang Berhubungan dengan Kenaikan CD4 pada Pasien HIV yang Mendapat Highly Active Antiretroviral Therapy dalam 6 bulan Pertama. *J Penyakit Da* 2015;2(4):217–222.
 53. Pratiwi NL, Basuki H. Hubungan Karakteristik Remaja Terkait Risiko Penularan HIV/AIDS dan Perilaku Seks Tidak Aman di Indonesia. *Humaniora* 2011;1:346-357
 54. Kamila N, Siwiendrayanti A. Persepsi Orang dengan HIV dan AIDS Terhadap Peran Kelompok Dukungan Sebaya. *J Kesehat Masy*. 2010;6(1):36–43.
 55. Dalimoenthe I. Perempuan dalam Cengkeraman HIV / AIDS : Kajian Sosiologi Feminis Perempuan Ibu Rumah Tangga. *Komunitas*. 2011;5(1):41–8.
 56. Anwar Y, Nugroho SA, Tantri ND. Karakteristik Sociodemografi, Klinis, dan Pola Terapi Antiretroviral Pasien HIV/AIDS di RSPI Prof. Dr. Sulianti Saroso Periode Januari-Juni 2016. *Pharm J Indones*. 2018;15(01):72–89.
 57. Fletcher C, Kakuda T, Anderson P. Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. *J Am Coll Nutr*. 2001;20(6):609–15.
 58. Anwar Y, Barus T, Ginting D. Evaluation of Antiretroviral Adverse Effects and Managements on HIV/AIDS Patients in Penjaringan District Primary. *Soc Clin Pharm Indones J*. 2017;2(1):29–37.

59. Yustika K. Evaluasi Penggunaan Antiretroviral Pada Pasien HIV/AIDS Di RSUD dr. Soehadi Prijonegoro Sragen Periode 2016- 2017. Universitas Sebelas Maret; 2017.
60. American Society for Microbiology. Pharmacokinetic Interaction between Rifampin and Zidovudine. 1993;37(7):1426-1430.
61. American Society for Microbiology. Rifampin Reduces Concentrations of Trimethoprim and Sulfamethoxazole in Serum in Human Immunodeficiency Virus-Infected Patients. 2001;45(11):3238-3241.
62. Yenny Y, Trisakti U, Agus N. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. *J Clin Pharmacol Ther.* 2011;49:162–168.
63. Syamsudin. Interaksi Obat Konsep Dasar dan Klinis. In Jakarta: Universitas Indonesia; 2011. p. 1–12.

